Fahri Küçükali

TL;DR: This paper performed a two-stage genome-wide association study with 111,326 clinically diagnosed/proxy AD cases and 677,663 controls and found 75 risk loci, of which 42 were new at the time of analysis.

TL;DR: In this article, a large genetic association study was performed by merging all available case-control datasets and by-proxy study results (discovery n = 409,435 and validation size n = 58,190).

TL;DR: A genome-wide significant association of 31 new loci with the risk of AD is reported, with the involvement of gene sets related to amyloid and Tau, but also microglia, in which increased gene expression corresponds to more significant AD risk.

TL;DR: The largest collaborative effort on genetics underlying CSF biomarkers was established by the European Alzheimer & Dementia Biobank (EADB), including 31 cohorts with a total of 13,116 individuals (discovery n = 8074; replication n = 5042 individuals) as discussed by the authors .

TL;DR: The large risk reductions reported here suggest that protein chemistry and functional assays of these variants should be pursued, as they have the potential to guide drug development targeting APOE.